Teleflex Incorporated (NYSE:TFX) Director Stephen K. M.D. Klasko sold 200 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $241.88, for a total transaction of $48,376.00. Following the completion of the sale, the director now directly owns 8,080 shares in the company, valued at $1,954,390.40. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Teleflex Incorporated (NYSE:TFX) traded down 0.19% during midday trading on Tuesday, reaching $244.25. 227,639 shares of the company’s stock traded hands. The firm has a market cap of $11.00 billion, a PE ratio of 46.71 and a beta of 1.07. The company has a 50 day moving average of $225.61 and a 200 day moving average of $208.48. Teleflex Incorporated has a 52-week low of $136.53 and a 52-week high of $246.67.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $2.04 EPS for the quarter, beating the Zacks’ consensus estimate of $1.91 by $0.13. The firm had revenue of $528.60 million during the quarter, compared to analysts’ expectations of $518.98 million. Teleflex had a return on equity of 16.12% and a net margin of 12.36%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.89 earnings per share. On average, equities analysts predict that Teleflex Incorporated will post $8.28 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Tuesday, August 15th were given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date of this dividend was Friday, August 11th. Teleflex’s payout ratio is 26.00%.

TRADEMARK VIOLATION WARNING: “Teleflex Incorporated (TFX) Director Sells $48,376.00 in Stock” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/03/teleflex-incorporated-tfx-director-sells-48376-00-in-stock.html.

Institutional investors and hedge funds have recently modified their holdings of the stock. Toronto Dominion Bank grew its position in Teleflex by 14.5% in the 2nd quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock valued at $115,000 after purchasing an additional 70 shares during the period. Advisory Services Network LLC increased its stake in Teleflex by 933.8% during the 2nd quarter. Advisory Services Network LLC now owns 827 shares of the medical technology company’s stock valued at $172,000 after purchasing an additional 747 shares in the last quarter. OLD Mutual Customised Solutions Proprietary Ltd. increased its stake in Teleflex by 200.0% during the 1st quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 900 shares of the medical technology company’s stock valued at $174,000 after purchasing an additional 600 shares in the last quarter. Cornerstone Capital Management Holdings LLC. bought a new stake in Teleflex during the 2nd quarter valued at $175,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in Teleflex during the 2nd quarter valued at $200,000. Institutional investors own 89.75% of the company’s stock.

A number of research firms have issued reports on TFX. Jefferies Group LLC reiterated a “buy” rating and set a $230.00 target price on shares of Teleflex in a report on Thursday, August 3rd. BidaskClub lowered Teleflex from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Needham & Company LLC restated a “buy” rating on shares of Teleflex in a report on Friday, August 4th. Stephens restated a “buy” rating and issued a $270.00 price target (up from $230.00) on shares of Teleflex in a report on Monday, September 25th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and set a $238.00 price objective (up from $220.00) on shares of Teleflex in a research report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. Teleflex currently has an average rating of “Buy” and an average target price of $260.75.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.